Navigation Links
XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome

SANTA CLARA, Calif.--(BUSINESS WIRE)--Apr 25, 2007 - XenoPort, Inc. (Nasdaq: XNPT) today announced top-line results from a Phase 3 clinical trial of XP13512 for the treatment of symptoms of primary restless legs syndrome (RLS). XP13512 demonstrated statistically significant improvements compared to placebo on both of the co-primary endpoints of the trial and was well tolerated.

"These results are very encouraging and represent a major advance for XenoPort, its partners and, potentially, RLS patients," said Ronald W. Barrett, Ph.D., chief executive officer of XenoPort.

This XenoPort study was a 12-week, double-blind, placebo-controlled Phase 3 clinical trial that enrolled 222 patients who were diagnosed with moderate-to-severe primary RLS. Patients were treated with either 1200 mg of XP13512 or placebo, given once per day. The co-primary endpoints for the clinical trial were the change from baseline for the International RLS (IRLS) rating scale score at end of treatment and the percentage of patients showing significant improvement on the Clinical Global Impression of Improvement (CGI-I) scale at end of treatment.

Treatment with 1200 mg of XP13512 was associated with a statistically significant improvement in the co-primary endpoints compared to placebo. Improvements in the IRLS Scale were significantly greater for XP13512 than for placebo (-13.2 vs. -8.8: p=0.0002). At the end of treatment, significantly more patients treated with XP13512 were reported as "much improved" or "very much improved" on the CGI-I scale compared to those treated with placebo (76% vs. 39%: p less than 0.0001).

During treatment over the 12-week period, the most commonly reported adverse events for XP13512 versus placebo were somnolence (26.5% XP13512; 7.4% placebo) and dizziness (19.5% XP13512; 4.6% placebo). There were no reported serious adverse events in XP13512-treated patients.

Dr. Barrett stated, "XP135
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:5/16/2013)... and ZURICH , May 17, 2013 /PRNewswire/ ... Science, Technology and Research (A*STAR) and Switzerland,s ... volunteer has been dosed in a Phase 1 clinical trial ... bacteriophage Qbeta virus-like particle (VLP) technology. In this first Phase ... vaccine candidate and its potential to protect against H1N1 influenza ...
(Date:5/16/2013)...  Nektar Therapeutics, (Nasdaq: NKTR ) President and ... is scheduled to present at the upcoming 2013 UBS Global ... the Sheraton New York Hotel on Tuesday, May 21, 2013 ... be accessible via a Webcast through a link posted in ... http://www.nektar.com . This Webcast will be available for replay ...
(Date:5/16/2013)... , May 16, 2013  Alere Inc. (NYSE: ... take charge of their health at home through the merger ... dividend of $3.00 per share on its Series B Convertible ... July 15, 2013 to holders of record of Series B ... Such payment will cover the amount of all ...
Breaking Medicine Technology:A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2
... Medical Alarm Concepts Holding, Inc. (OTCQB: MDHI.PK) today issued an ... with Carrollton, Texas based FirstFitness Nutrition Inc., a leading provider ... While both companies continue to move forward with ... both sides. Originally, the merger was projected to be finished ...
...  Nouveau Life Pharmaceuticals, soon to be changed from Hybrid Fuels, ... it is hiring a team of consumer marketing experts to ... portfolio of products to the market place. The ... and consumer education strategy for the Azul Instant™ product.  Consumer ...
Cached Medicine Technology:Medical Alarm Concepts Provides Update to Investors 2Medical Alarm Concepts Provides Update to Investors 3HRID Announces Growth and Expansion 2HRID Announces Growth and Expansion 3
(Date:5/19/2013)... 2013 According to a new ... Forecast (2013 – 2018): By Applications (Healthcare (Endoscopy, ... (CCD, CMOS, Contact IS, Infrared, X-Ray) And Geography" ... market was $8.00 billion in 2012 and is ... an estimated CAGR of 3.84% from 2013 to ...
(Date:5/19/2013)... May 19, 2013 Fat Burning Furnace ... program that provides people with fat burning diet ... order this Fat Burning Furnace package, people will receive ... they can download quickly. The Fat Burning Furnace manual ... people build lean muscle mass. In addition, this book ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Dr. Keith Chertok ... help fight their unhealthy gums and increase the chance of ... Laser Assisted New Attachment Procedure (LANAP) not only removes diseased ... and strengthens the jaw bone for dental implants. ... diseased gum tissue. It can also help stimulate the healthy ...
(Date:5/19/2013)... 2013 Agora Health Limited developed by Rachael ... on how to increase memory power naturally and ... that helps people re-new their entire health from the inside ... caused by a fatigued mind. In addition, the program helps ... a lifetime. The author claimed that this program can help ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Buenos Aires, Argentina: ... be offered in Buenos Aires, Argentina by the ... Sánchez de Bustamante 2372 - (Barrio Norte). Classes are ... The Yoga classes are offered in a calm environment, ... breathing exercises, and healthy vegetarian food, among others. , ...
Breaking Medicine News(10 mins):Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Fat Burning Diet | How “Fat Burning Furnace” Helps People Lose Their Weight Naturally And Fast – V-kool 2Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2Health News:How To Increase Memory Power | How “Agora Health Limited” Helps People Improve Their Memory Naturally And Effectively – Health Review 2Health News:Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center 2
... ... of their new, pharmaceutical website, featuring an extensive selection of medications for the treatment ... ... popularly sold medications, with a particular emphasis on Erectile Dysfunction treatments. Erectile dysfunction, ...
... 9 The medical imaging market in Kenya is ... driven by an aging population demanding greater access to ... in the market remain high due to the sizeable ... financial constraints faced by many healthcare institutions in the ...
... 8 The Council for American Medical Innovation applauds President ... of life-threatening illnesses in Muslim nations. , , ... , In his address to the Muslim nation in ... must recognize that education and innovation will be the currency ...
... , SALT LAKE CITY, June 8 Qqest Software Systems ... company,s TimeForce time and attendance software, as well as the ... Colorado GI performs over 5,000 medical procedures each year. Prior ... were using a manual time clock and paper time cards ...
... KUNMING, China, June 8 /PRNewswire-Asia-FirstCall/ ... KUN) ("China Shenghuo" or,the "Company"), which is engaged ... nutritional supplement and cosmetic products,in the People,s Republic ... Amex,LLC (the "NYSE Amex" or "Exchange") has accepted ...
... Attorney General Eric Holder will be honored and deliver brief remarks ... Ceremony on TUESDAY, JUNE 9, 2009 at ... will present the Joel A. Toubin Memorial Award to the Attorney ... Holder , , WHAT: To be honored and ...
Cached Medicine News:Health News:Pro-Medics Launches Its New Line of Male Impotence Treatment Products 2Health News:Frost & Sullivan: Replacement of Old Equipment Boosts Kenyan Medical Imaging Industry 2Health News:Frost & Sullivan: Replacement of Old Equipment Boosts Kenyan Medical Imaging Industry 3Health News:Frost & Sullivan: Replacement of Old Equipment Boosts Kenyan Medical Imaging Industry 4Health News:Council for American Medical Innovation Applauds President Obama's Pledge to Invest in Science, Technology and Health Abroad 2Health News:Colorado Gastroenterology Chooses Qqest's TimeForce, Payroll Services 2Health News:NYSE Amex Accepts China Shenghuo's Compliance Plan for Continued Listing 2Health News:NYSE Amex Accepts China Shenghuo's Compliance Plan for Continued Listing 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: